Squarepoint
CRL icon

Squarepoint’s Charles River Laboratories CRL Stock Holding History

Squarepoint’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,600
Closed -$720K – 4361
2025
Q3 		$720K Sell
4,600
-5,900
-56% -$937K ﹤0.01% 2931
2025
Q2 		$1.59M Buy
+10,500
New +$1.4M ﹤0.01% 2265
2024
Q2 		– Sell
-3,200
Closed -$867K – 4147
2024
Q1 		$867K Buy
+3,200
New +$764K ﹤0.01% 2692

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Squarepoint's CRL Position: Q1 2026 in Review

Squarepoint reduced its Charles River Laboratories (CRL) stake by 0.3% in Q1 2026, selling an estimated $742 and leaving 1,308 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #3897.

Squarepoint first reported a position in CRL in Q2 2015 and has held it in 35 quarters since. The position peaked at $17.6M in Q1 2022. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Squarepoint held 1,308 shares of Charles River Laboratories worth $226K as of Q1 2026.
  • Squarepoint sold 4 Charles River Laboratories shares in Q1 2026, an estimated $742.
  • Charles River Laboratories made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3897 holding.
  • Squarepoint first reported a position in Charles River Laboratories in Q2 2015 and has held it in 35 quarters since.
  • Squarepoint's Charles River Laboratories position peaked at $17.6M in Q1 2022.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.